Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2024 07:39 ET | Source: Recursion Pharmaceuticals, Inc.

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a...
June 24, 2024 08:00 ET | Source: Recursion Pharmaceuticals, Inc.

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nominationBayer to become first...
April 16, 2024 08:00 ET | Source: Recursion Pharmaceuticals, Inc.

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development,...
March 11, 2024 04:00 ET | Source: Recursion Pharmaceuticals, Inc.

Recursion Announces Plans to Open New Office in London

LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new...
January 04, 2024 07:59 ET | Source: Recursion Pharmaceuticals, Inc.

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline

SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed...
November 09, 2023 08:01 ET | Source: Recursion Pharmaceuticals, Inc.

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two...